Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART101 in healthy adult subjects
NCT07529600Phase 1Completed
- Sponsor
- Arnatar Therapeutics
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ART101 in hypertension (HTN) (5 arms), sponsored by Arnatar Therapeutics. Primary endpoints: Adverse Events and Serious Adverse Events at Day 169 and Abnormal Laboratory Values at Day 169. Started Jan 2024; status: completed.
02
Drugs
ART101
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07529600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529600.